Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys
Copyright: © 2024 Ji et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..
PF-07209960 is a novel bispecific fusion protein composed of an anti-PD-1 antibody and engineered IL-15 cytokine mutein with reduced binding affinity to its receptors. The pharmacokinetics (PK), pharmacodynamics (PD), and toxicity of PF-07209960 were evaluated following once every other week subcutaneous (SC) or intravenous (IV) administration to cynomolgus monkeys in a repeat-dose PKPD (0.01-0.3 mg/kg/dose) and GLP toxicity study (0.1-3 mg/kg/dose). PF-07209960 showed dose dependent pharmacokinetics with a terminal T1/2 of 8 and 13 hours following IV administration at 0.03 and 0.1 mg/kg, respectively. The clearance is faster than a typical IgG1 antibody. Slightly faster clearance was also observed following the second dose, likely due to increased target pool and formation of anti-drug antibodies (ADA). Despite a high incidence rate of ADA (92%) observed in GLP toxicity study, PD-1 receptor occupancy, IL-15 signaling (STAT5 phosphorylation) and T cell expansion were comparable following the first and second doses. Activation and proliferation of T cells were observed with largest increase in cell numbers found in gamma delta T cells, followed by CD4+ and CD8+ T cells, and then NK cells. Release of cytokines IL-6, IFNγ, and IL-10 were detected, which peaked at 72 hours postdose. There was PF-07209960-related mortality at ≥1 mg/kg. At scheduled necropsy, microscopic findings were generalized mononuclear infiltration in various tissues. Both the no observed adverse effect level (NOAEL) and the highest non severely toxic dose (HNSTD) were determined to be 0.3 mg/kg/dose, which corresponded to mean Cmax and AUC48 values of 1.15 μg/mL and 37.9 μg*h/mL, respectively.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
PloS one - 19(2024), 2 vom: 27., Seite e0298240 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ji, Changhua [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 07.02.2024 Date Revised 07.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0298240 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368049523 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368049523 | ||
003 | DE-627 | ||
005 | 20240207232324.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240206s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0298240 |2 doi | |
028 | 5 | 2 | |a pubmed24n1283.xml |
035 | |a (DE-627)NLM368049523 | ||
035 | |a (NLM)38315680 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ji, Changhua |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2024 | ||
500 | |a Date Revised 07.02.2024 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright: © 2024 Ji et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | ||
520 | |a PF-07209960 is a novel bispecific fusion protein composed of an anti-PD-1 antibody and engineered IL-15 cytokine mutein with reduced binding affinity to its receptors. The pharmacokinetics (PK), pharmacodynamics (PD), and toxicity of PF-07209960 were evaluated following once every other week subcutaneous (SC) or intravenous (IV) administration to cynomolgus monkeys in a repeat-dose PKPD (0.01-0.3 mg/kg/dose) and GLP toxicity study (0.1-3 mg/kg/dose). PF-07209960 showed dose dependent pharmacokinetics with a terminal T1/2 of 8 and 13 hours following IV administration at 0.03 and 0.1 mg/kg, respectively. The clearance is faster than a typical IgG1 antibody. Slightly faster clearance was also observed following the second dose, likely due to increased target pool and formation of anti-drug antibodies (ADA). Despite a high incidence rate of ADA (92%) observed in GLP toxicity study, PD-1 receptor occupancy, IL-15 signaling (STAT5 phosphorylation) and T cell expansion were comparable following the first and second doses. Activation and proliferation of T cells were observed with largest increase in cell numbers found in gamma delta T cells, followed by CD4+ and CD8+ T cells, and then NK cells. Release of cytokines IL-6, IFNγ, and IL-10 were detected, which peaked at 72 hours postdose. There was PF-07209960-related mortality at ≥1 mg/kg. At scheduled necropsy, microscopic findings were generalized mononuclear infiltration in various tissues. Both the no observed adverse effect level (NOAEL) and the highest non severely toxic dose (HNSTD) were determined to be 0.3 mg/kg/dose, which corresponded to mean Cmax and AUC48 values of 1.15 μg/mL and 37.9 μg*h/mL, respectively | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
650 | 7 | |a Interleukin-15 |2 NLM | |
650 | 7 | |a Cytokines |2 NLM | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
700 | 1 | |a Kuang, Bing |e verfasserin |4 aut | |
700 | 1 | |a Buetow, Bernard S |e verfasserin |4 aut | |
700 | 1 | |a Vitsky, Allison |e verfasserin |4 aut | |
700 | 1 | |a Xu, Yuanming |e verfasserin |4 aut | |
700 | 1 | |a Huang, Tzu-Hsuan |e verfasserin |4 aut | |
700 | 1 | |a Chaparro-Riggers, Javier |e verfasserin |4 aut | |
700 | 1 | |a Kraynov, Eugenia |e verfasserin |4 aut | |
700 | 1 | |a Matsumoto, Diane |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 19(2024), 2 vom: 27., Seite e0298240 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2024 |g number:2 |g day:27 |g pages:e0298240 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0298240 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2024 |e 2 |b 27 |h e0298240 |